After 24 weeks, statistically significant improvements in FEV1 AUC0–3 response (P<0.0001) and trough FEV1 response (P<0.01) were demonstrated with olodaterol 5 μg, olodaterol 10 μg, and formoterol versus placebo
Olodaterol 5 μg via Respimat®
Placebo
FEV1 